

BWC Antibiogram 2023

GRAM NEGATIVE		ANTIBIOTICS														
1/1/2023-12/31/2023	Number tested	Amoxicillin/Clavulanic Acid	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin ^(b)	Levofloxacin	Meropenem	Nitrofurantoin	Piperacillin/Tazobactam	Tetracycline	Tobramycin ^(b)	Trimeth/Sulfa
ORGANISM	PERCENT SUSCEPTIBLE															
<i>Enterobacter cloacae</i> complex	43	•	•	•	95	•	90	90	95	89	100	31	•	86	94	93
<i>Escherichia coli</i>	613	83	50	81	90	86	68	100	90	66	100	96	96	72	88	73
<i>Escherichia coli (ED urine only)</i>	184	84	50	84	92	88	74	100	88	72	100	95	96	74	85	74
<i>Klebsiella pneumoniae</i>	172	91	0	83	89	86	79	98	95	76	98	22	89	72	91	84
<i>Proteus mirabilis</i>	55	89	64	91	100	91	82	100	100	82	100	0	100	0	100	82
<i>Pseudomonas aeruginosa</i> ^(b)	92				92		73			64	87		95		98	

GRAM POSITIVE		ANTIBIOTICS							
Organism	Number tested	Ampicillin	Clindamycin	Gentamycin (High-Level)	Linezolid	Nitrofurantoin	Oxacillin	Trimeth/Sulfa	Vancomycin
Organism	PERCENT SUSCEPTIBLE								
<i>Enterococcus faecalis</i>	109	98		81	96	97			96
<i>Staphylococcus aureus, ALL</i>	160		70		100		64	95	100
<i>MRSA only</i>	61		74		100		0	94	100
<i>MSSA only</i>	99		71		100		100	100	100
<i>Staphylococcus epidermidis</i>	67		67		100		34	66	100

85-100% Susceptible

60-84% Susceptible

<60% Susceptible

• Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated

Shaded boxes indicate organism/antimicrobial combines not tested routinely

Denotes manufacturer reporting limitation

(a) Data with fewer than 30 isolates has poor statistical validity.

(b) Aminoglycoside breakpoints lowered for Enterobacterales and *Pseudomonas aeruginosa* in 2023. Gentamicin is no longer a reliable treatment option for *Pseudomonas aeruginosa*.